Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Others

Ratios

Bone Biologics (BBLG) Share-based Compensation (2016 - 2025)

Bone Biologics has reported Share-based Compensation over the past 2 years, most recently at $209626.0 for Q4 2017.

Quarterly Share-based Compensation fell 82.6% to $209626.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$2.5 million through Dec 2017, down 159.24% year-over-year, with the annual reading at $256358.0 for FY2025, 35.77% up from the prior year.
Share-based Compensation was $209626.0 for Q4 2017 at Bone Biologics, down from $367157.0 in the prior quarter.
Over five years, Share-based Compensation peaked at $1.2 million in Q4 2016 and troughed at -$3.5 million in Q2 2017.